Scientech Research LLC Buys 15,924 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Scientech Research LLC grew its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 102.7% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 31,435 shares of the company’s stock after acquiring an additional 15,924 shares during the quarter. Scientech Research LLC owned about 0.05% of Twist Bioscience worth $1,549,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. EdgeRock Capital LLC acquired a new position in shares of Twist Bioscience during the 2nd quarter worth $43,000. Blue Trust Inc. raised its holdings in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after buying an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of Twist Bioscience during the 2nd quarter worth $61,000. Nisa Investment Advisors LLC raised its holdings in shares of Twist Bioscience by 31.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after buying an additional 546 shares in the last quarter. Finally, CWM LLC raised its holdings in shares of Twist Bioscience by 27.4% during the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after buying an additional 524 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Robert W. Baird upped their target price on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Guggenheim initiated coverage on Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 target price for the company. The Goldman Sachs Group upped their target price on Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. Finally, Barclays lowered their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $48.22.

Twist Bioscience Trading Up 3.1 %

Shares of TWST stock opened at $47.08 on Friday. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -14.01 and a beta of 1.76. The stock has a 50-day moving average of $46.46 and a 200-day moving average of $43.24. Twist Bioscience Co. has a 1-year low of $14.42 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. During the same quarter in the previous year, the company earned ($1.01) EPS. The firm’s revenue for the quarter was up 27.7% on a year-over-year basis. Sell-side analysts forecast that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,114 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $48.00, for a total transaction of $53,472.00. Following the sale, the chief executive officer now owns 504,732 shares in the company, valued at approximately $24,227,136. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Twist Bioscience news, CEO Emily M. Leproust sold 1,114 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $48.00, for a total value of $53,472.00. Following the transaction, the chief executive officer now owns 504,732 shares in the company, valued at $24,227,136. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Adam Laponis sold 842 shares of the stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $48.91, for a total value of $41,182.22. Following the completion of the transaction, the chief financial officer now owns 73,602 shares in the company, valued at approximately $3,599,873.82. The disclosure for this sale can be found here. Insiders have sold a total of 17,386 shares of company stock worth $770,915 in the last 90 days. Corporate insiders own 3.92% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.